Skip to content

Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas

Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02497664
Acronym
ABC
Enrollment
22
Registered
2015-07-14
Start date
2016-01-31
Completion date
2016-12-31
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Lung Cancer

Keywords

Radiotherapy, Active Breathing Control Technique

Brief summary

Neo-adjuvant chemoradiotherapy (neo-CRT) is increasingly applied in the curative treatment of esophageal cancer, with the aim to downstage the tumor, to increase the rate of radical resections, and consequently to improve the survival rates. Due to improved survival, it will become increasingly important to minimize the radiation-induced toxicity among long-term survivors. In the management of locally advanced non small cell lung cancer (NSCLC), radiotherapy is the standard treatment modality. However, the dose that can be safely applied to the tumour is limited by the risk of cardiac and pulmonary complications, which even led to decreased survival in a randomised study, when a higher tumor dose was administered \[1\]. Radiation induced pulmonary and cardiac toxicity are the most important late side effects after thoracic radiotherapy \[2-4\]. The aim of this study is to reduce the radiation dose of heart (and lungs) in order to reduce the toxicity risk. In recent years, the active breathing control (ABC) technique has been introduced in the radiotherapy for left sided breast cancer patients, to minimize the radiation dose to the heart. These patients are irradiated in the inspiration phase, in which the distance between the heart and the breast is largest, while the lungs extend. Breath hold might also be beneficial for radiotherapy of esophageal and lung tumors. For these patients the expiratory phase might theoretically be more beneficial to reduce the heart dose. However, the inspiration phase might be better for the dose to the lungs, which consequently allows cardiac dose reduction.

Interventions

Sponsors

University Medical Center Groningen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically proven esophageal cancer (adeno-, or squamous cell carcinoma) of the mid or distal esophagus or stage III NSCLC (any histological subtype). * Scheduled for external-beam photon radiotherapy with curative intention. * WHO 0-2. * Age \>= 18 years * Written informed consent.

Exclusion criteria

* Serious respiratory distress * Noncompliance with any of the inclusion criteria.

Design outcomes

Primary

MeasureTime frame
Mean Hart Dose (MHD)At 6 weeks after start of radiation therapy

Secondary

MeasureTime frameDescription
Mean Lung Dosis (MLD)At 6 weeks after start of radiation therapy
Position of the heart in relation to the target volumesAt 6 weeks after start of radiation therapy
Internal Target Volume (ITV) margin (margin for breathing movement defined as ITV - Gross Tumor Volume (GTV))At 6 weeks after start of radiation therapy
Dose Volume Histogram (DVH) parameters of the heartAt 6 weeks after start of radiation therapyV5, V10, V20, V30, V40, V50, V60

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026